Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 512

1.

Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Hossain MS, Jaye DL, Pollack BP, Farris AB, Tselanyane ML, David E, Roback JD, Gewirtz AT, Waller EK.

J Immunol. 2011 Nov 15;187(10):5130-40. doi: 10.4049/jimmunol.1101334. Epub 2011 Oct 17.

2.

[Prophylactic effect of TLR5 agonist flagellin on acute graft versus host disease after allogeneic hematopoietic stem cell transplantation and its mechanism].

Gong XD, Ma LM, Zhu L, Guo HM, Ren LS, Ren RR, Zhang HP, Wei F, Niu YY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Aug;20(4):965-70. Chinese.

PMID:
22931665
3.

A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.

Ding X, Bian G, Leigh ND, Qiu J, McCarthy PL, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X.

J Immunol. 2012 Nov 15;189(10):4719-27. doi: 10.4049/jimmunol.1201206. Epub 2012 Oct 8.

4.

Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.

Roback JD, Hossain MS, Lezhava L, Gorechlad JW, Alexander SA, Jaye DL, Mittelstaedt S, Talib S, Hearst JE, Hillyer CD, Waller EK.

J Immunol. 2003 Dec 1;171(11):6023-31.

5.

Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.

Turner BE, Kambouris ME, Sinfield L, Lange J, Burns AM, Lourie R, Atkinson K, Hart DN, Munster DJ, Rice AM.

Transplantation. 2008 Oct 15;86(7):968-76. doi: 10.1097/TP.0b013e3181874787.

PMID:
18852664
6.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.

Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28.

PMID:
18573173
7.

Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection.

Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC.

PLoS One. 2013 Apr 15;8(4):e61841. doi: 10.1371/journal.pone.0061841. Print 2013.

8.

Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.

Fricke S, Rothe K, Hilger N, Ackermann M, Oelkrug C, Fricke C, Schönfelder U, Niederwieser D, Emmrich F, Sack U.

Cytometry A. 2012 Jun;81(6):476-88. doi: 10.1002/cyto.a.22061. Epub 2012 Apr 20. Erratum in: Cytometry A. 2015 Mar;87(3):279-80.

9.

Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.

Yang D, Wang LP, Zhou H, Cheng H, Bao XC, Xu S, Zhang WP, Wang JM.

Cell Transplant. 2015;24(9):1717-31. doi: 10.3727/096368914X684592. Epub 2014 Sep 8.

PMID:
25203502
10.

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

Giver CR, Montes RO, Mittelstaedt S, Li JM, Jaye DL, Lonial S, Boyer MW, Waller EK.

Biol Blood Marrow Transplant. 2003 Oct;9(10):616-32.

11.

Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.

Wang J, Li L, Xu M, Rong R, Zhu T.

Transplantation. 2013 Nov 15;96(9):774-81. doi: 10.1097/TP.0b013e3182a1931f.

12.

The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.

Nguyen VH, Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M, Brown JM, Negrin RS.

Blood. 2008 Jan 15;111(2):945-53. Epub 2007 Oct 4.

14.

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.

Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.

Biol Blood Marrow Transplant. 2003 Dec;9(12):742-52.

15.

Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.

Yang J, Gao L, Liu Y, Ren Y, Xie R, Fan H, Qian K.

Transfusion. 2010 Feb;50(2):407-17. doi: 10.1111/j.1537-2995.2009.02395.x. Epub 2009 Sep 24.

PMID:
19788510
16.

Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.

Wang H, Asavaroengchai W, Yeap BY, Wang MG, Wang S, Sykes M, Yang YG.

Blood. 2009 Apr 9;113(15):3612-9. doi: 10.1182/blood-2008-07-168419. Epub 2009 Feb 10.

18.

Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.

Tian Y, Deng YB, Huang YJ, Wang Y.

Immunol Invest. 2008;37(1):29-42. doi: 10.1080/08820130701410223.

PMID:
18214798
19.

Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.

Hossain MS, Ramachandiran S, Gewirtz AT, Waller EK.

PLoS One. 2014 May 30;9(5):e96165. doi: 10.1371/journal.pone.0096165. eCollection 2014.

20.

Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).

Azar Y, Shainer R, Almogi-Hazan O, Bringer R, Compton SR, Paidas MJ, Barnea ER, Or R.

Biol Blood Marrow Transplant. 2013 Apr;19(4):519-28. doi: 10.1016/j.bbmt.2012.12.011. Epub 2012 Dec 21.

Supplemental Content

Support Center